

ATTENDANCE, PROXY AND ADVANCE VOTE CARD

Shareholder number:

Number of shares:

[bar code]

The 2026 Annual Shareholders' Meeting of International Consolidated Airlines Group, S.A. will be held on **18 June 2026 at 12 noon (CEST)**, on second call, in the event that the legally required quorum is not reached and therefore the meeting cannot be held on the first call that is hereby scheduled for 17 June 2026 at 12 noon (CEST). Shareholders are informed that **the Shareholders' Meeting will be held on second call.**

The Shareholders' Meeting is to be held in Madrid, at Auditorio Rafael del Pino, Calle de Rafael Calvo 39A, with the option of attending remotely.

If you attend the Shareholders' Meeting in person, you must give this card at the entrance to the venue on the day the meeting is held. If you attend the Shareholders' Meeting remotely, the platform for remote attendance will be enabled on the "Annual Shareholders' Meeting 2026" section on the Company's website (www.iairgroup.com), through the Remote Attendance tab.

If you are not attending the meeting physically or remotely in person and wish to appoint a proxy or vote in advance, you must complete and sign the relevant section below: proxy or advance vote. Please note that only one section should be filled out. After duly completing the card in the appropriate section, you must send the original attendance, proxy and remote vote card by post or e-mail, with the relevant section duly completed and signed, to the Shareholder Office (IAG) (calle Martínez Villergas, 49, 28027 Madrid) or by e-mail to accionistas@iairgroup.com.

You can also appoint a proxy or cast your vote prior to the Shareholders' Meeting electronically, on the Company's website (www.iairgroup.com), by following the instructions given and using your electronic DNI (DNIE) or your digital signature based on a recognized and valid certificate issued by the Spanish Public Certification Entity (CERES) attached to *Fábrica Nacional de Moneda y Timbre*.

PROXY

The shareholder hereby delegates its representation to the Chairman of the Board of Directors (or, in his absence, the person standing in for him as Chairman of the Shareholders' Meeting), unless another proxy is specified here:

The representative is hereby given specific instructions to vote for all the proposed resolutions prepared by the Board of Directors unless specified otherwise below (*check the appropriate boxes*):

Item on the agenda	1	2	3	4	5	6	7	8	8.a)	8.b)	8.c)	8.d)	8.e)	8.f)	8.g)	8.h)	8.i)	8.j)	8.k)	9	10	11	12	13.a)	13.b)	14
For																										
Against																										
Abstention																										

The delegation covers any items not listed on the attached agenda that may legally arise, with respect to which the representative shall vote in the direction they deem most favourable to the interests of the shareholder, unless specified otherwise here:

In the event of conflict of interest of the representative, the proxy shall be understood to be successively given to the Chairman of the Shareholders' Meeting, the Secretary of the Shareholders' Meeting or the Deputy Secretary of the Board.

For the purposes of Articles 523 and 526 of the Companies Act (*Ley de Sociedades de Capital*), it is placed on record that the Chairman of the Board of Directors and the other directors may have a conflict of interest in relation to item 9 (*Consultative vote on the 2025 annual report on directors' remuneration*) on the agenda, and with respect to proposals for their removal or for any company action for liability that may be brought against them as permitted by law and the directors whose re-election or appointment is proposed under items 8.a) to 8.k) on the agenda are affected by a conflict of interest in connection with their own re-election or appointment.

Shareholder's signature

Proxy's signature

Shareholder number:

Number of shares:

On , 2026

On , 2026

[bar code]

ADVANCE VOTE

The shareholder votes in favour of all the proposed resolutions prepared by the Board of Directors, unless specified otherwise below (*check the appropriate boxes*):

Item on the agenda	1	2	3	4	5	6	7	8.a)	8.b)	8.c)	8.d)	8.e)	8.f)	8.g)	8.h)	8.i)	8.j)	8.k)	9	10	11	12	13.a)	13.b)	14
For																									
Against																									
Abstention																									

With respect to any items not listed on the attached agenda that may legally arise, it will be deemed that the Chairman of the Board of Directors (or, in his absence, the person standing in for him as Chairman of the Shareholders' Meeting) has been appointed to vote on the shareholder's behalf, unless specified otherwise here: The representative will vote in the direction they deem most favourable to the interests of the shareholder, unless specified otherwise here: In the event of conflict of interest of the representative, the proxy shall be understood to be successively given to the Chairman of the Shareholders' Meeting, the Secretary of the Shareholders' Meeting or the Deputy Secretary of the Board.

For the purposes of Articles 523 and 526 of the Companies Act (*Ley de Sociedades de Capital*), it is placed on record that the Chairman of the Board of Directors and the other directors may have a conflict of interest with respect to proposals for their removal or for any company action for liability that may be brought against them as permitted by the law.

Shareholder's signature

On , 2026

Shareholder number:

Number of shares:

[bar code]

AGENDA FOR THE 2026 ANNUAL SHAREHOLDERS' MEETING

Annual accounts, corporate management and auditor

1. Approval of the 2025 financial statements and management reports of the Company and of its consolidated group.
2. Approval of the consolidated non-financial information statement and sustainability information report for financial year 2025.
3. Approval of the management of the Board of Directors during the 2025 financial year.
4. Re-election of KPMG Auditores, S.L. as auditor of the Company and of its consolidated group for financial year 2026 and delegation of powers.

Shareholder remuneration

5. Approval of the proposal for the allocation of 2025 results.
6. 2025 final dividend approval.
7. Approval of a reduction in share capital by means of the cancellation of up to 461,166,953 shares (10 per cent of the share capital). Delegation of powers for the implementation thereof.

Directors' re-election, appointment and resolutions on directors' remuneration

8. Re-election and appointment of directors for the Corporate Bylaws mandated one-year term:
 - a. To re-elect Mr Javier Ferrán as non-executive independent director.
 - b. To re-elect Mr Luis Gallego as executive director.
 - c. To re-elect Ms Eva Castillo as non-executive independent director.
 - d. To re-elect Ms Margaret Ewing as non-executive independent director.
 - e. To re-elect Mr Maurice Lam as non-executive independent director.
 - f. To re-elect Mr Bruno Matheu as non-executive proprietary director.
 - g. To re-elect Ms Heather Ann McSharry as non-executive independent director.
 - h. To re-elect Ms Simone Menne as non-executive independent director.
 - i. To re-elect Mr Robin Phillips as non-executive proprietary director.
 - j. To re-elect Ms Päivi Rekonen as non-executive independent director.
 - k. To appoint Mr Daniel Pinto as non-executive independent director.
9. Consultative vote on the 2025 annual report on directors' remuneration.

Authorisations for the acquisition of own shares, for the issuance of shares and convertible or exchangeable securities and for the exclusion of pre-emptive rights

10. Authorisation for the derivative acquisition of the Company's own shares by the Company itself and/or by its subsidiaries.
11. Authorisation to the Board of Directors, with the express power of substitution, to increase the share capital pursuant to the provisions of Article 297.1 b) of the Spanish Companies Law.
12. Authorisation to the Board of Directors, with the express power of substitution, to issue securities (including warrants) convertible into and/or exchangeable for shares of the Company. Establishment of the criteria for determining the basis for and the terms and conditions applicable to the conversion or exchange.
13. Authorisation to the Board of Directors, with the express power of substitution, to exclude pre-emptive rights in connection with the capital increases and the issuances of convertible or exchangeable securities that the Board of Directors may approve under the authorities given under resolutions 11 and 12:
 - a. Up to 10 per cent of the share capital on an unrestricted basis.
 - b. Up to an additional 10 per cent of the share capital to be used for either an acquisition or a specified capital investment.

Delegation of powers

14. Delegation of powers to formalise and execute all resolutions adopted by the Shareholders' Meeting.